Jakob Ödén
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jakob Ödén has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Suryakant Kaushik
Department of Research RaySearch Laboratories AB Stockholm Sweden
3 shared publications - Ane Lindegaard Appelt
Department of Oncology, Centre for Cancer and Organ Diseases, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark; Department of Health Technology, Technical University of Denmark, Copenhagen, Denmark
2 shared publications - Christopher J H Pagett
Medical Physics, Leeds Teaching Hospitals NHS Trust, Leeds Cancer Centre, Leeds, England, LS7 9TF, United Kingdom of Great Britain and Northern Ireland
2 shared publications - Iuliana Toma-Dasu
Medical Radiation Physics, Stockholm University and Karolinska Institutet, Stockholm, Sweden
2 shared publications - John Lilley
Department of Medical Physics, Leeds Teaching Hospitals NHS Trust, Beckett Street, Leeds, LS9 7TF, UK
2 shared publications Kjell Eriksson
Department of Research RaySearch Laboratories AB Stockholm Sweden
2 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 71 (19) , 195023
Dosimetric validation of proton beam deflection and field shape deformation in a measured transverse magnetic field of an in-beam MR scanner using a novel dose calculation functionality in a research version of a commercial treatment planning system
Objective. Integrating in-beam magnetic resonance imaging (MRI) with proton therapy (PT) introduces magnetic fields (MFs) that affect proton beam transport and therefore require accurate incorporation into the treatment planning system (TPS) for magnetic resonance (MR)-integrated PT (MRiPT). This study experimentally validates Monte Carlo-based proton dose calculation in the presence of the MF in a research version of the commercial TPS RayStation for MRiPT, using a measured three-dimensional (3D) magnetic vector field map of a 0.32 T in-beam MR scanner combined with a horizontal proton pencil beam scanning beam line. Approach. An MR-compatible mapping framework was used to acquire a high-resolution 3D magnetic vector field map, subsequently implemented into the TPS following coordinate transformations. Proton spot patterns and square radiation fields at 100, 150, and 220 MeV were delivered with and without the MF present. Dose distributions in air were measured using a 2D ionisation chamber array at multiple positions and compared with TPS dose calculations by analysing lateral beam shifts and field shape deformations with local γ -analysis. Clinically relevant patient treatment fields were evaluated at different water-equivalent depths (WEDs) in a phantom. Main results. Implementation of the measured magnetic vector field map preserved field vector magnitude, orientation and spatial alignment within the TPS. Dose measurements showed energy- and position-dependent MF-induced effects, which were accurately reproduced by the TPS. Agreement in lateral beam shifts was within 1–3 mm, and γ -pass rates exceeded 97% for a 3%/3 mm local criterion (10% dose threshold). Similar agreement was observed for patient treatment fields throughout all WEDs. Significance. This work validates the TPS capability to accurately model MF-induced proton beam transport in air as well as in a water-equivalent phantom. The present workflow establishes a foundation for proton treatment planning in the presence of MFs and thereby contributes to the clinical implementation of MRiPT.
- 7 October 2026
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 71 (19) , 195023
Open AccessDosimetric validation of proton beam deflection and field shape deformation in a measured transverse magnetic field of an in-beam MR scanner using a novel dose calculation functionality in a research version of a commercial treatment planning system
Objective. Integrating in-beam magnetic resonance imaging (MRI) with proton therapy (PT) introduces magnetic fields (MFs) that affect proton beam transport and therefore require accurate incorporation into the treatment planning system (TPS) for magnetic resonance (MR)-integrated PT (MRiPT). This study experimentally validates Monte Carlo-based proton dose calculation in the presence of the MF in a research version of the commercial TPS RayStation for MRiPT, using a measured three-dimensional (3D) magnetic vector field map of a 0.32 T in-beam MR scanner combined with a horizontal proton pencil beam scanning beam line. Approach. An MR-compatible mapping framework was used to acquire a high-resolution 3D magnetic vector field map, subsequently implemented into the TPS following coordinate transformations. Proton spot patterns and square radiation fields at 100, 150, and 220 MeV were delivered with and without the MF present. Dose distributions in air were measured using a 2D ionisation chamber array at multiple positions and compared with TPS dose calculations by analysing lateral beam shifts and field shape deformations with local γ -analysis. Clinically relevant patient treatment fields were evaluated at different water-equivalent depths (WEDs) in a phantom. Main results. Implementation of the measured magnetic vector field map preserved field vector magnitude, orientation and spatial alignment within the TPS. Dose measurements showed energy- and position-dependent MF-induced effects, which were accurately reproduced by the TPS. Agreement in lateral beam shifts was within 1–3 mm, and γ -pass rates exceeded 97% for a 3%/3 mm local criterion (10% dose threshold). Similar agreement was observed for patient treatment fields throughout all WEDs. Significance. This work validates the TPS capability to accurately model MF-induced proton beam transport in air as well as in a water-equivalent phantom. The present workflow establishes a foundation for proton treatment planning in the presence of MFs and thereby contributes to the clinical implementation of MRiPT.
- Open Access
- 12 December 2025
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 37
Isotoxic stereotactic reirradiation for recurrent pelvic cancers
- 12 December 2025
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 37
Open AccessIsotoxic stereotactic reirradiation for recurrent pelvic cancers
- Open Access
- 10 October 2025
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 36, 100847
Synthetic computed tomography techniques for adaptive proton therapy in head and neck cancers
- 10 October 2025
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 36, 100847
Open AccessSynthetic computed tomography techniques for adaptive proton therapy in head and neck cancers
- Open Access
- 3 November 2024
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 26 (1) , e14535
Beyond a constant proton relative biological effectiveness: A survey of clinical and research perspectives among proton institutions in Europe and the United States
Purpose: Although proton relative biological effectiveness (RBE) depends on factors like linear energy transfer (LET), tissue properties, dose, and biological endpoint, a constant RBE of 1.1 is recommended in clinical practice. This study surveys proton institutions to explore activities using functionalities beyond a constant proton RBE.Methods: Research versions of RayStation integrate functionalities considering variable proton RBE, LET, proton track‐ends, and dirty dose. A survey of 19 institutions in Europe and the United States, with these functionalities available, investigated clinical adoption and research prospects using a 25‐question online questionnaire.Results: Of the 16 institutions that responded (84% response rate), 13 were clinically active. These clinical institutions prescribe RBE = 1.1 but also employ planning strategies centered around special beam arrangements to address potentially enhanced RBE effects in serially structured organs at risk (OARs). Clinical plan evaluation encompassed beam angles/spot position (69%), dose‐averaged LET (LETd) (46%), and variable RBE distributions (38%). High ratings (discrete scale: 1–5) were reported for the research functionalities using linear LETd‐RBE models, LETd, track‐end frequency and dirty dose (averages: 4.0–4.8), while LQ‐based phenomenological RBE models dependent on LETd scored lower for optimization (average: 2.2) but congruent for evaluation (average: 4.1). The institutions preferred LET reported as LETd (94%), computed in unit‐density water (56%), for all protons (63%), and lean toward LETd‐based phenomenological RBE models for clinical use (> 50%).Conclusions: Proton institutions recognize RBE variability but adhere to a constant RBE while actively mitigating potential enhancements, particularly in serially structured OARs. Research efforts focus on planning techniques that utilize functionalities beyond a constant RBE, emphasizing standardized LET and RBE calculations to facilitate their adoption in clinical practice and improve clinical data collection. LETd calculated in unit‐density water for all protons as input to adaptable phenomenological RBE models was the most suggested approach, aligning with predominant clinical LET and variable RBE reporting.
- 3 November 2024
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 26 (1) , e14535
Open AccessBeyond a constant proton relative biological effectiveness: A survey of clinical and research perspectives among proton institutions in Europe and the United States
Purpose: Although proton relative biological effectiveness (RBE) depends on factors like linear energy transfer (LET), tissue properties, dose, and biological endpoint, a constant RBE of 1.1 is recommended in clinical practice. This study surveys proton institutions to explore activities using functionalities beyond a constant proton RBE.Methods: Research versions of RayStation integrate functionalities considering variable proton RBE, LET, proton track‐ends, and dirty dose. A survey of 19 institutions in Europe and the United States, with these functionalities available, investigated clinical adoption and research prospects using a 25‐question online questionnaire.Results: Of the 16 institutions that responded (84% response rate), 13 were clinically active. These clinical institutions prescribe RBE = 1.1 but also employ planning strategies centered around special beam arrangements to address potentially enhanced RBE effects in serially structured organs at risk (OARs). Clinical plan evaluation encompassed beam angles/spot position (69%), dose‐averaged LET (LETd) (46%), and variable RBE distributions (38%). High ratings (discrete scale: 1–5) were reported for the research functionalities using linear LETd‐RBE models, LETd, track‐end frequency and dirty dose (averages: 4.0–4.8), while LQ‐based phenomenological RBE models dependent on LETd scored lower for optimization (average: 2.2) but congruent for evaluation (average: 4.1). The institutions preferred LET reported as LETd (94%), computed in unit‐density water (56%), for all protons (63%), and lean toward LETd‐based phenomenological RBE models for clinical use (> 50%).Conclusions: Proton institutions recognize RBE variability but adhere to a constant RBE while actively mitigating potential enhancements, particularly in serially structured OARs. Research efforts focus on planning techniques that utilize functionalities beyond a constant RBE, emphasizing standardized LET and RBE calculations to facilitate their adoption in clinical practice and improve clinical data collection. LETd calculated in unit‐density water for all protons as input to adaptable phenomenological RBE models was the most suggested approach, aligning with predominant clinical LET and variable RBE reporting.
- Open Access
- 13 September 2024
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 69 (18) , 185010
Adaptive intensity modulated proton therapy using 4D robust planning: a proof-of-concept for the application of dose mimicking approach
Objective. A four-dimensional robust optimisation (4DRO) is usually employed when the tumour respiratory motion needs to be addressed. However, it is computationally demanding, and an automated method is preferable for adaptive planning to avoid manual trial-and-error. This study proposes a 4DRO technique based on dose mimicking for automated adaptive planning. Approach. Initial plans for 4DRO intensity modulated proton therapy were created on an average CT for four patients with clinical target volume (CTV) in the lung, oesophagus, or pancreas, respectively. These plans were robustly optimised using three phases of four-dimensional computed tomography (4DCT) and accounting for setup and density uncertainties. Weekly 4DCTs were used for adaptive replanning, using a constant relative biological effectiveness (cRBE) of 1.1. Two methods were used: (1) template-based adaptive (TA) planning and (2) dose-mimicking-based adaptive (MA) planning. The plans were evaluated using variable RBE (vRBE) weighted doses and biologically consistent dose accumulation (BCDA). Main results. MA and TA plans had comparable CTV coverage except for one patient where the MA plan had a higher D98 and lower D2 but with an increased D2 in few organs at risk (OARs). CTV D98 deviations in non-adaptive plans from the initial plans were up to −7.2 percentage points (p.p.) in individual cases and −1.8 p.p. when using BCDA. For the OARs, MA plans showed a reduced mean dose and D2 compared to the TA plans, with few exceptions. The vRBE-weighted accumulated doses had a mean dose and D2 difference of up to 0.3 Gy and 0.5 Gy, respectively, in the OARs with respect to cRBE-weighted doses. Significance. MA plans indicate better performance in target coverage and OAR dose sparing compared to the TA plans in 4DRO adaptive planning. Moreover, MA method is capable of handling both forms of anatomical variation, namely, changes in density and relative shifts in the position of OARs.
- 13 September 2024
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 69 (18) , 185010
Open AccessAdaptive intensity modulated proton therapy using 4D robust planning: a proof-of-concept for the application of dose mimicking approach
Objective. A four-dimensional robust optimisation (4DRO) is usually employed when the tumour respiratory motion needs to be addressed. However, it is computationally demanding, and an automated method is preferable for adaptive planning to avoid manual trial-and-error. This study proposes a 4DRO technique based on dose mimicking for automated adaptive planning. Approach. Initial plans for 4DRO intensity modulated proton therapy were created on an average CT for four patients with clinical target volume (CTV) in the lung, oesophagus, or pancreas, respectively. These plans were robustly optimised using three phases of four-dimensional computed tomography (4DCT) and accounting for setup and density uncertainties. Weekly 4DCTs were used for adaptive replanning, using a constant relative biological effectiveness (cRBE) of 1.1. Two methods were used: (1) template-based adaptive (TA) planning and (2) dose-mimicking-based adaptive (MA) planning. The plans were evaluated using variable RBE (vRBE) weighted doses and biologically consistent dose accumulation (BCDA). Main results. MA and TA plans had comparable CTV coverage except for one patient where the MA plan had a higher D98 and lower D2 but with an increased D2 in few organs at risk (OARs). CTV D98 deviations in non-adaptive plans from the initial plans were up to −7.2 percentage points (p.p.) in individual cases and −1.8 p.p. when using BCDA. For the OARs, MA plans showed a reduced mean dose and D2 compared to the TA plans, with few exceptions. The vRBE-weighted accumulated doses had a mean dose and D2 difference of up to 0.3 Gy and 0.5 Gy, respectively, in the OARs with respect to cRBE-weighted doses. Significance. MA plans indicate better performance in target coverage and OAR dose sparing compared to the TA plans in 4DRO adaptive planning. Moreover, MA method is capable of handling both forms of anatomical variation, namely, changes in density and relative shifts in the position of OARs.
- 20 February 2024
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 119 (5) , 1530-1544
A Novel Framework for Thermoradiotherapy Treatment Planning
- 20 February 2024
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 119 (5) , 1530-1544
A Novel Framework for Thermoradiotherapy Treatment Planning
- Open Access
Brain Re-Irradiation Robustly Accounting for Previously Delivered Dose
(1) Background: The STRIDeR (Support Tool for Re-Irradiation Decisions guided by Radiobiology) planning pathway aims to facilitate anatomically appropriate and radiobiologically meaningful re-irradiation (reRT). This work evaluated the STRIDeR pathway for robustness compared to a more conservative manual pathway. (2) Methods: For ten high-grade glioma reRT patient cases, uncertainties were applied and cumulative doses re-summed. Geometric uncertainties of 3, 6 and 9 mm were applied to the background dose, and LQ model robustness was tested using α/β variations (values 1, 2 and 5 Gy) and the linear quadratic linear (LQL) model δ variations (values 0.1 and 0.2). STRIDeR robust optimised plans, incorporating the geometric and α/β uncertainties during optimisation, were also generated. (3) Results: The STRIDeR and manual pathways both achieved clinically acceptable plans in 8/10 cases but with statistically significant improvements in the PTV D98% (p < 0.01) for STRIDeR. Geometric and LQ robustness tests showed comparable robustness within both pathways. STRIDeR plans generated to incorporate uncertainties during optimisation resulted in a superior plan robustness with a minimal impact on PTV dose benefits. (4) Conclusions: Our results indicate that STRIDeR pathway plans achieved a similar robustness to manual pathways with improved PTV doses. Geometric and LQ model uncertainties can be incorporated into the STRIDeR pathway to facilitate robust optimisation.
Open AccessBrain Re-Irradiation Robustly Accounting for Previously Delivered Dose
(1) Background: The STRIDeR (Support Tool for Re-Irradiation Decisions guided by Radiobiology) planning pathway aims to facilitate anatomically appropriate and radiobiologically meaningful re-irradiation (reRT). This work evaluated the STRIDeR pathway for robustness compared to a more conservative manual pathway. (2) Methods: For ten high-grade glioma reRT patient cases, uncertainties were applied and cumulative doses re-summed. Geometric uncertainties of 3, 6 and 9 mm were applied to the background dose, and LQ model robustness was tested using α/β variations (values 1, 2 and 5 Gy) and the linear quadratic linear (LQL) model δ variations (values 0.1 and 0.2). STRIDeR robust optimised plans, incorporating the geometric and α/β uncertainties during optimisation, were also generated. (3) Results: The STRIDeR and manual pathways both achieved clinically acceptable plans in 8/10 cases but with statistically significant improvements in the PTV D98% (p < 0.01) for STRIDeR. Geometric and LQ robustness tests showed comparable robustness within both pathways. STRIDeR plans generated to incorporate uncertainties during optimisation resulted in a superior plan robustness with a minimal impact on PTV dose benefits. (4) Conclusions: Our results indicate that STRIDeR pathway plans achieved a similar robustness to manual pathways with improved PTV doses. Geometric and LQ model uncertainties can be incorporated into the STRIDeR pathway to facilitate robust optimisation.